Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.

Keywords

Medicine, Immunology, Epitope, Major histocompatibility complex, MHC class I

References

• Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.Brian K. Martin, John G. Frelinger, Jenny P.‐Y. Ting — 1999
• Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.Sivasubramanian Baskar, Virginia K. Clements, L H Glimcher — 1996
• Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.Virginia K. Clements, Sivasubramanian Baskar, Todd D. Armstrong — 1992
• Proteolysis and antigen presentation by MHC class II moleculesPaula Wolf Bryant, Ana‐Maria Lennon‐Duménil, Edda Fiebiger — 2004
• A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cellJ P Ridge, Francesca Di Rosa, Polly Matzinger — 1998
• Loss of colonic HLA antigens in familial adenomatous polyposis.George J. Tsioulias, Thomas A. Godwin, Marjorie F. Goldstein — 1992
• Interleukin 2 Gene Therapy for Prostate Cancer: Phase I Clinical Trial and Basic BiologyArie S. Belldegrun, Cho-Lea Tso, Amnon Zisman — 2001
• Discordant expression of Ii and HLA-DR in thyrocytes: A possible pathogenetic factor in Hashimoto’s thyroiditisMujun Yu, Mingzhen Xu, Lou Savas — 1998
• Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resectionWilliam R. Jarnagin, Jonathan S. Zager, David S. Klimstra — 2003
• Mice lacking the MHC class II-associated invariant chain.Stéphane Viville, Jacques Neefjes, Vincent Lotteau — 1993
• More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release.Masanori Daibata, Minzhen Xu, Robert E. Humphreys — 1994
• A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanomaAlok A. Khorana, Joseph D. Rosenblatt, Deepak M. Sahasrabudhe — 2003
• Ionizing Radiation Greatly Improves Gene Transfer Efficiency in Mammalian CellsCraig W. Stevens, Ming Zeng, George J. Cerniglia — 1996
• Genetic control of MHC class II expression.Jenny Pan-Yun Ting, John Trowsdale — 2002
• Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cellsGang Qiu, John Goodchild, Robert E. Humphreys — 1999
• MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice.Sivasubramanian Baskar, V. Azarenko, Elizabeth Marshall — 1994
• Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.Axel Heiser, Doris Coleman, Jens Dannull — 2002
• Induction of MHC class I expression by the MHC class II transactivator CIITA.Brian K. Martin, Keh-Chuang Chin, John C. Olsen — 1997
• Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancerPierre L. Triozzi, Reema Khurram, Wayne Aldrich — 2000
• Mixed growth hormone cell- prolactin cell pituitary adenoma with acromegaly: α-subunit most growth hormone cellsShigeru Furuhata, Toru Kameya, Tomoko Tsuruta — 1992

Cited by

• Low expression of HLA‐DRA, HLA‐DPA1, and HLA‐DPB1 is associated with poor prognosis in pediatric adrenocortical tumors (ACT)Fabíola A. Leite, Régia Caroline Peixoto Lira, Paola Fernanda Fedatto — 2014
• Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.Christina Lönnroth, Marianne Andersson, Annette Arvidsson — 2008
• CD4+ T cells in antitumor immunity: utility of an Ii-Key HER2/neu hybrid peptide vaccine (AE37)Elizabeth A. Mittendorf, Jarrod P. Holmes, James L. Murray — 2009
• Cysteine cathepsins: regulators of antitumour immune responseNataša Obermajer, Bojan Doljak, Janko Kos — 2006
• Curative Antitumor Immune Response Is Optimal with Tumor Irradiation Followed by Genetic Induction of Major Histocompatibility Complex Class I and Class II Molecules and Suppression of Ii ProteinYu Wang, Minzhen Xu, Mingxin Che — 2005
• Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin AManolis Gialitakis — 2006
• Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II‐negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin‐12Sadamu Homma, Hideo Komita, Yukiko Sagawa — 2005
• Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.Steve Rickard, Santa Jeremy Ono — 2008
• HLA class II antigen presentation by prostate cancer cellsAustin R Younger, Shereen Amria, W A Jeffrey — 2008
• HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor ImmunotherapyBently P. Doonan, Azizul Haque — 2010
• Genome-Wide Transcription Responses to Synchrotron Microbeam RadiotherapyCarl N. Sprung, Yuqing Yang, Helen B. Forrester — 2012
• MHC class II molecules and tumour immunotherapyIrena Oven — 2005
• Radiation Improves Intratumoral Gene Therapy for Induction of Cancer Vaccine in Murine Prostate CarcinomaGilda G. Hillman, Minzhen Xu, Yu Wang — 2003
• Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.Robert E. Humphreys, Gilda G. Hillman, Eric von Hofe — 2004
• Ovarian cancer and the immune system - The role of targeted therapies.T.B. Turner, Donald J. Buchsbaum, J. Michael Straughn — 2016
• Tumor cell transformation using antisense oligonucleotide.Mohamed R. Akl, Nehad M. Ayoub — 2014
• Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewHaller J. Smith, J. Michael Straughn, Donald J. Buchsbaum — 2017
• The anti-tumor effects of entinostat in ovarian cancer require adaptive immunityHaller J. Smith, Tyler R. McCaw, Angelina I. Londoño — 2018
• The small molecule antibody mimic SH7139 targets a family of HLA-DRs expressed by B-cell lymphomas and other solid cancersRod Balhorn, Monique Cosman Balhorn, K. Balakrishnan — 2020
• Comprehensive Analysis of Immune-Related Metabolic Genes in Lung AdenocarcinomaFangfang Li, Chun Fa Huang, Lingxiao Qiu — 2021

Related papers

• The Major Histocompatibility Complex of Old World Camels—A SynopsisMartin Plášil, Sofia Wijkmark, Jean P. Elbers — 2019
• Mechanisms of MHC class I‐restricted antigen processing and cross‐presentationPeter Cresswell, Anne L. Ackerman, Alessandra Giodini — 2005
• Neurons Preferentially Respond to Self-MHC Class I Allele Products Regardless of Peptide PresentedNathalie Escande‐Beillard, Lorraine Washburn, Dan Zekzer — 2009
• Human Herpesvirus 7 U21 Tetramerizes To Associate with Class I Major Histocompatibility Complex MoleculesNathan A. May, Qiuhong Wang, Andrea Balbo — 2014
• NetMHCpan, a method for MHC class I binding prediction beyond humansIlka Hoof, Bjoern Peters, John Sidney — 2008
• Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteinsFengwen Zhang, Trinity Zang, Eva M. Stevenson — 2022
• The Assessment of Major Histocompatibility Complex (MHC) Class-I Expression in Different Neuromuscular DiseasesMaher Kurdi, Aysha A. Alshareef, Ahmed K. Bamaga — 2021
• Prediction of MHC class I binding peptides, using SVMHCPierre Dönnes, Arne Elofsson — 2002